Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: Rifampicin, rifabutin, and rifapentine
- 1 December 2011
- journal article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 82 (11), 1747-1756
- https://doi.org/10.1016/j.bcp.2011.08.003
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Human Paraoxonase 1 Is the Enzyme Responsible for Pilocarpine HydrolysisDrug Metabolism and Disposition, 2011
- Activation of Pregnane X Receptor (PXR) and Constitutive Androstane Receptor (CAR) by Herbal MedicinesThe AAPS Journal, 2009
- An acetylation/deacetylation cycle controls the export of sterols and steroids from S. cerevisiaeThe EMBO Journal, 2007
- Human CYP1B1 Is Regulated by Estradiol via Estrogen ReceptorCancer Research, 2004
- Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin AntibacterialsClinical Pharmacokinetics, 2001
- Rabbit Serum Paraoxonase 3 (PON3) Is a High Density Lipoprotein-associated Lactonase and Protects Low Density Lipoprotein against OxidationPublished by Elsevier BV ,2000
- Rifampin and rifabutin and their metabolism by human liver esterasesXenobiotica, 1997
- The Human Serum Paraoxonase/Arylesterase Gene (PON1) Is One Member of a Multigene FamilyGenomics, 1996
- Purification and characterization of a human liver arylacetamide deacetylaseBiochemical and Biophysical Research Communications, 1991
- Action of Fluoride on Cholinesterase. I. On the Mechanism of Inhibition.Acta Chemica Scandinavica, 1965